12,541 Shares in The Beauty Health Company (NASDAQ:SKIN) Purchased by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. bought a new position in The Beauty Health Company (NASDAQ:SKIN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,541 shares of the company’s stock, valued at approximately $326,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC bought a new position in shares of Beauty Health in the second quarter worth approximately $308,817,000. Vanguard Group Inc. bought a new position in shares of Beauty Health in the second quarter worth approximately $119,177,000. Redmile Group LLC bought a new position in shares of Beauty Health in the second quarter worth approximately $106,735,000. BlackRock Inc. bought a new position in shares of Beauty Health in the second quarter worth approximately $58,045,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of Beauty Health in the second quarter worth approximately $41,814,000. Hedge funds and other institutional investors own 62.08% of the company’s stock.

Several research analysts have recently weighed in on SKIN shares. Zacks Investment Research raised shares of Beauty Health from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a report on Thursday. Stifel Nicolaus started coverage on shares of Beauty Health in a report on Thursday, October 7th. They set a “buy” rating and a $33.00 price objective for the company. DA Davidson boosted their price objective on shares of Beauty Health from $26.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 10th. Cowen started coverage on shares of Beauty Health in a report on Monday, October 4th. They set an “outperform” rating and a $32.00 price objective for the company. Finally, William Blair started coverage on shares of Beauty Health in a report on Friday, January 7th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, Beauty Health currently has a consensus rating of “Buy” and a consensus target price of $28.22.

Shares of SKIN stock opened at $15.24 on Friday. The Beauty Health Company has a 12 month low of $9.71 and a 12 month high of $30.17. The company has a 50 day simple moving average of $24.01 and a two-hundred day simple moving average of $23.53.

Beauty Health (NASDAQ:SKIN) last announced its earnings results on Monday, November 8th. The company reported ($1.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($1.60). The business had revenue of $68.15 million for the quarter, compared to analyst estimates of $59.57 million. As a group, research analysts predict that The Beauty Health Company will post -0.09 earnings per share for the current year.

Beauty Health Profile

Edge Systems, LLC designs, develops, manufactures, markets, and sells aesthetic technologies and products. It offers hydradermabrasion system that enhances the skin to cleanse, exfoliate, extract, and hydrate simultaneously; Hydraglucan Intense Hydration Booster, a customization for the HydraFacial treatment exfoliates the skin by improving cell renewal and delivers ingredients, including hyaluronic acid, glucan, and betaine to hydrate the skin and provide anti-aging benefits; HydraFacial Daily Essentials, which provides detoxification, rejuvenation, and protection of skin; crystal microdermabrasion systems; and light emitting diode systems.

Featured Story: Exchange-Traded Funds (ETFs)

Institutional Ownership by Quarter for Beauty Health (NASDAQ:SKIN)

Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.